Valuation: Autolus Therapeutics plc

Market Cap 655M 561M 525M 480M 902M 62.65B 913M 6.2B 2.42B 31.47B 2.46B 2.41B 104B P/E 2026 *
-3.06x
P/E 2027 * -3.61x
Enterprise Value 655M 561M 525M 480M 902M 62.65B 913M 6.2B 2.42B 31.47B 2.46B 2.41B 104B EV / Sales 2026 *
4.37x
EV / Sales 2027 * 3.4x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -
1 day-2.24%
1 week+11.86%
Current month+61.41%
1 month+64.16%
3 months+45.76%
6 months+39.02%
Current year+20.85%
1 week 2.13
Extreme 2.13
2.58
1 month 1.41
Extreme 1.41
2.58
Current year 1.18
Extreme 1.175
2.58
1 year 1.18
Extreme 1.175
2.58
3 years 1.1
Extreme 1.105
7.45
5 years 1.1
Extreme 1.105
7.9
10 years 1.1
Extreme 1.105
53.24
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 01/09/2014
Chief Executive Officer 61 01/03/2016
Director of Finance/CFO 56 07/08/2023
Director TitleAgeSince
Chairman 61 01/10/2014
Director/Board Member 78 01/08/2014
Director/Board Member 71 01/03/2018
Date Insider Type Main position Quantity % Market Cap.
29/6/26 Free

Director

79,167 0.0477%
18/3/26 Other

Director

310,000 0.1866%
18/3/26 Other

General Counsel

780,818 0.4700%
Change 5-day change 1-year change 3-year change Capi.($)
-2.24%+11.86%+37.43%-25.54% 655M
+0.89%+3.71%+39.30%-1.32% 82.54B
-1.69%+22.38%-23.76%-37.80% 58.38B
+8.35%+130.61%+456.90%+31.45% 53.23B
-1.46%-0.83%-1.01%+30.84% 52.24B
+1.74%+1.19%+13.58%+175.40% 48.52B
+1.11%+3.41%+55.98%-18.14% 31.67B
+0.46%+6.75%+48.24%+97.70% 25.79B
+1.19%+7.62%+8.19%+225.60% 22.46B
-5.74%+0.79%-1.19%+842.24% 16.97B
Average +0.33%+16.26%+63.37%+132.04% 39.25B
Weighted average by Cap. +1.07%+19.96%+76.41%+78.40%

Financials

2026 *2027 *
Net sales 150M 128M 120M 110M 206M 14.33B 209M 1.42B 553M 7.2B 562M 550M 23.81B 192M 165M 154M 141M 265M 18.41B 268M 1.82B 711M 9.25B 723M 707M 30.59B
Net income -219M -187M -175M -161M -301M -20.94B -305M -2.07B -808M -10.52B -822M -804M -34.79B -185M -159M -149M -136M -255M -17.74B -259M -1.76B -685M -8.91B -696M -681M -29.47B
Net Debt - -
Logo Autolus Therapeutics plc
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
Employees
753
Date Price Change Volume
22/08/26 USD 2.405 -2.24% 2,103,064
20/08/26 USD 2.460 -3.15% 3,254,202
19/08/26 USD 2.540 +10.92% 7,840,758
18/08/26 USD 2.290 +0.44% 3,363,410
17/08/26 USD 2.280 +6.05% 3,036,041
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
2.460USD
Average target price
8.725USD
Spread / Average Target
+254.67%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AUTL Stock